From the molecule to the clinic inhibiting HER2 to treat breast cancer

New England Journal of Medicine

Volumn 344, Issue 11, 2001, Pages 841-842

  Eisenhauer, E A ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HEART DISEASES; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS;

EID: 0035869520     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200103153441110     Document Type: Editorial

References (14)

1. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
2. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
3. HER2 causes transformation and tumorigenesis of NIH 3T3 cells
4. Humanization of an anti-p185HER2 antibody for human cancer therapy
5. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
6. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
7. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridization assays
8. Her-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization
9. Construction and validation of a practical prognostic index for patients with metastatic breast cancer
10. On receptor inhibitors and chemotherapy
11. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast-cancer
12. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
13. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs